Company Profile
Amicus Therapeutics Stock Price, News & Analysis
Company overview
Business overview
Amicus Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Amicus Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Amicus Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Amicus Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
FOLD is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Amicus's catalysts are Pombiliti plus Opfolda commercial uptake and continued Galafold execution in Fabry disease. The company is trying to prove that its rare-disease platform can keep compounding beyond a single product cycle.
Recent news
The five most recent feed items are shown below in reverse chronological order.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.